Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

117.53
Delayed Data
As of Jan 19
 +2.44 / +2.12%
Today’s Change
55.00
Today|||52-Week Range
121.18
+17.21%
Year-to-Date
Wall Street Associates Buys PGT Innovations Inc, Carbonite Inc, Obalon Therapeutics I...
Jan 18 / GuruFocus News - Paid Partner Content
Incyte's Prospects Get Even Brighter With Merck Announcement
Jan 10 / MotleyFool.com - Paid Partner Content
4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal
Jan 10 / Zacks.com - Paid Partner Content
3 Stocks Expected to More Than Double Their Earnings in 2017
Jan 08 / MotleyFool.com - Paid Partner Content
Incyte/Merck to Start More Epacadostat-Keytruda Studies
Jan 10 / Zacks.com - Paid Partner Content
Biotech Investing: 3 Bold Predictions for 2017
Jan 06 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close115.09
Today’s open115.50
Day’s range113.00 - 117.62
Volume1,160,019
Average volume (3 months)1,412,201
Market cap$22.1B
Dividend yield--
Data as of 01/19/2017

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+2,001.67%
Earnings growth (next 5 years)+94.65%
Revenue growth (last year)+47.36%
P/E ratio148.8
Price/Sales26.95
Price/Book128.17

Competitors

 Today’s
change
Today’s
% change
VRTXVertex Pharmaceutica...-1.61-1.95%
MYLMylan NV-0.24-0.65%
BAXBaxter International...-0.20-0.43%
ZTSZoetis Inc+0.20+0.38%
Data as of 01/19/2017

Financials

Next reporting dateFebruary 16, 2017
EPS forecast (this quarter)$0.13
Annual revenue (last year)$753.8M
Annual profit (last year)$6.5M
Net profit margin0.87%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts


Search for Jobs